References
- Chancey AL, Brower GL, Peterson JT, et al. (2002). Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation 105:1983–8
- Choi YH, Cowan DB, Moran AM, et al. (2009). Myocyte apoptosis occurs early during the development of pressure-overload hypertrophy in infant myocardium. J Thorac Cardiovasc Surg 137:1356–62
- Condorelli G, Morisco C, Stassi G, et al. (1999). Increased cardiomyocyte apoptosis and changes in proapoptotic and antiapoptotic genes bax and bcl-2 during left ventricular adaptations to chronic pressure overload in the rat. Circulation 99:3071–8
- Creemers EE, Cleutjens JP, Smits JF, et al. (2001). Matrix metalloproteinase inhibition after myocardial infarction: A new approach to prevent heart failure? Circ Res 89:201–10
- Derosa G, D’Angelo A, Ciccarelli L, et al. (2006). Matrix metalloproteinase-2,-9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium 13:227–31
- Kim HE, Dalal SS, Young E, et al. (2000). Disruption of the myocardial extracellular matrix leads to cardiac dysfunction. J Clin Invest 106:857–66
- Koren MJ, Devereux RB, Casale PN, et al. (1991). Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Inter Med 114:345–52
- Li S, Zhang Z, Wu L, et al. (2007). Understanding ZHENG in traditional Chinese medicine in the context of neuro-endocrineimmune network. IET Sys Biol 1:51–60
- Liu ZF, Li CM, Li M, et al. (2004). The subchronic toxicity of hydroxysafflor yellow A of 90 days repeatedly intraperitoneal injections in rats. Toxicology 203:139–43
- Liu S, Pereira NA, Teo JJ, et al. (2007). Mitochondrially targeted Bcl-2 and Bcl-X(L) chimeras elicit different apoptotic responses. Mol Cells 24:378–87
- Pearson AC, Pasierski T, Labovitz AJ. (1991). Left ventricular hypertrophy: Prognosis and management. Am Heart J 121:148–57
- Pu Y, Jin M. (2005). Study of hydroxysafflower yellow A improves myocardial ischemia. Chin Herbal Med 35:374–475
- Sano M, Minamino T, Toko H, et al. (2007). p53-Induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 446:444–8
- Song Y, Zhang L, Qu K, et al. (2005). Hydroxysafflor yellow A promotes vascular endothelial cell proliferation via VEGF/VEGF receptor. J Chin Pharm Sci 14:181–5
- Tian J, Jang W, Wang Z, et al. (2003). Effects of safflower flavone on local cerebral ischemia and thrombosis formation in rats. Chin Trad Herb Drugs 34:741–3
- Verdecchia P, Carini G, Circo A, et al.; MAVI (MAssa Ventricolare sinistra nell'Ipertensione) Study Group. (2001). Left ventricular mass and cardiovascular morbidity in essential hypertension: The MAVI study. J Am Coll Cardiol 38:1829–35
- Wei XB, Liu HQ, Sun X, et al. (2005). Hydroxysafflor yellow A protects rat brains against ischemia--reperfusion injury by antioxidant action. Neurosci Lett 386:58–62
- Xiao WY. (2006). Investigative progress of safflor yellow. Proc Clin Med J 15:646–9
- Xu CH, Zhang SF, Ma EM. (2005). Protective effect of safflor yellow A on myocardial ischemical reperfusion injury of rats. Chin J Clin Rehabil 43:93–5
- Zang B, Jin M, Si N, et al. (2002). Platelet activating factor receptor binding can be antagonized by HSYA. Acta Pharm Sin 37:696–9
- Zervoudaki A, Economou E, Stefanadis C, et al. (2003). Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J Hum Hypertens 17:119–24
- Zheng WC, Chen DB, Zhang L, et al. (2005). The effects and mechanism of safflor yellow A on myocardial ischemia. Chin Pharmacol Bull 21:978–80
- Zhou T, Li S. (2007). Multi-target recognition in intracellular regulation networks. Tsinghua Sci Technol 12:629–37